- SolnAb™ antibody platform reached PCC, continuously expanding the antibody drug candidate pool.
- SolnNuc™ Intelligent Nucleic Acid Drug Development Platform launched, entering the small nucleic acid therapeutics space.
- SolnZyme™ Enzyme Engineering Platform launched, expanding industrial applications of enzyme preparations.
- Established strategic partnerships with multiple pharmaceutical companies to advance the translational deployment of small nucleic acid and enzyme optimization technologies.
- Tendon stem cell drug candidate completed national filing.
- Launched Longevity Clinic, achieving a closed-loop model of "R&D–Production–Application."
- National High-Tech Enterprise status pending approval.
- Class II medical device approval received.
2026
- Built an in-house AI computing center with a thousand-GPU cluster to support platform R&D.
- World's first tendon stem cell (TSPC) IIT clinical trial approved for initiation at the Second Affiliated Hospital of Zhejiang University.
- PLLA microsphere facial injectable Class III medical device clinical trial approved.
- Invested in Huadao Biotechnology, Zhitang Technology, and Shanwan Biotechnology, strategically expanding into cell and gene therapy.
2025
- Established AI-driven de novo antibody discovery platform and R&D system.
- Developed AI-assisted biomaterial design platform.
- Founded Aiprui Biotechnology, focusing on advanced biomaterials and medical aesthetics & wellness.
- Incubated Wiselytics Intelligent Technology, focusing on neuromodulation and electrical stimulation R&D.
- Recognized as "Zhejiang Provincial Science & Technology SME."
2024
- Established AI-assisted musculoskeletal repair platform.
- Incubated CoJump Sports Medicine and Starlight Aesthetics Center.
- Completed the province's largest sports medicine rehabilitation facility.
- Built an industrial portfolio covering sports medicine, regenerative medicine, and medical aesthetics.
2023
- SUNRAY Biotechnology established, committed to data intelligence-driven biopharmaceutical innovation.
2022
- SolnAb™ antibody platform reached PCC, continuously expanding the antibody drug candidate pool.
- SolnNuc™ Intelligent Nucleic Acid Drug Development Platform launched, entering the small nucleic acid therapeutics space.
- SolnZyme™ Enzyme Engineering Platform launched, expanding industrial applications of enzyme preparations.
- Established strategic partnerships with multiple pharmaceutical companies to advance the translational deployment of small nucleic acid and enzyme optimization technologies.
- Tendon stem cell drug candidate completed national filing.
- Launched Longevity Clinic, achieving a closed-loop model of "R&D–Production–Application."
- National High-Tech Enterprise status pending approval.
- Class II medical device approval received.
2026
- Built an in-house AI computing center with a thousand-GPU cluster to support platform R&D.
- World's first tendon stem cell (TSPC) IIT clinical trial approved for initiation at the Second Affiliated Hospital of Zhejiang University.
- PLLA microsphere facial injectable Class III medical device clinical trial approved.
- Invested in Huadao Biotechnology, Zhitang Technology, and Shanwan Biotechnology, strategically expanding into cell and gene therapy.
2025
- Established AI-driven de novo antibody discovery platform and R&D system.
- Developed AI-assisted biomaterial design platform.
- Founded Aiprui Biotechnology, focusing on advanced biomaterials and medical aesthetics & wellness.
- Incubated Wiselytics Intelligent Technology, focusing on neuromodulation and electrical stimulation R&D.
- Recognized as "Zhejiang Provincial Science & Technology SME."
2024
- Established AI-assisted musculoskeletal repair platform.
- Incubated CoJump Sports Medicine and Starlight Aesthetics Center.
- Completed the province's largest sports medicine rehabilitation facility.
- Built an industrial portfolio covering sports medicine, regenerative medicine, and medical aesthetics.
2023
- SUNRAY Biotechnology established, committed to data intelligence-driven biopharmaceutical innovation.
2022
